| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399040 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(8 months ago) | |
| US9278101 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(8 months ago) | |
| US8173707 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(8 months ago) | |
| US8586633 | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jul, 2023
(8 months ago) | |
|
US8173707 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(2 months ago) | |
|
US8586633 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(2 months ago) | |
|
US9278101 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(2 months ago) | |
|
US9399040 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(2 months ago) | |
| US9855246 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
| US9486406 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
| US9066856 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
|
US9066856 (Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(10 years from now) | |
|
US9486406 (Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(10 years from now) | |
Omidria is owned by Rayner Surgical.
Omidria contains Ketorolac Tromethamine; Phenylephrine Hydrochloride.
Omidria has a total of 13 drug patents out of which 8 drug patents have expired.
Expired drug patents of Omidria are:
- US9399040
- US9278101
- US8173707
- US8586633
- US8173707*PED
- US8586633*PED
- US9278101*PED
- US9399040*PED
Omidria was authorised for market use on 30 May, 2014.
Omidria is available in solution;irrigation dosage forms.
Omidria can be used as maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
The generics of Omidria are possible to be released after 23 April, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2017 |
| New Patient Population(NPP) | Dec 08, 2020 |
| Pediatric Exclusivity(PED) | Jun 08, 2021 |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: Maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain
Dosage: SOLUTION;IRRIGATION
OMIDRIA family patents
